Related references
Note: Only part of the references are listed.Comparison of Cross-Platform Flow Cytometry Minimal Residual Disease Evaluation in Multiple Myeloma Using a Common Antibody Combination and Analysis Strategy
Stephanie Mathis et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2015)
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
Joaquin Martinez-Lopez et al.
BLOOD (2014)
Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of IGH
David Wu et al.
CLINICAL CANCER RESEARCH (2014)
Assessment of normal erythropoiesis by flow cytometry: important considerations for specimen preparation
J. R. Wangen et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2014)
Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing
Stephen J. Salipante et al.
MODERN PATHOLOGY (2014)
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission
Roland B. Walter et al.
BLOOD (2013)
Detection of Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia
Giuseppe Gaipa et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2013)
Combined flow cytometric assessment of CD45, HLA-DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes
Alex F. Sandes et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2013)
Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study
Andy C. Rawstron et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
Monique Terwijn et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL
A. C. Rawstron et al.
LEUKEMIA (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting
N. Feller et al.
BLOOD CANCER JOURNAL (2013)
Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group
Michael R. Loken et al.
BLOOD (2012)
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia
Malek Faham et al.
BLOOD (2012)
EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols
T. Kalina et al.
LEUKEMIA (2012)
High-Throughput Sequencing Detects Minimal Residual Disease in Acute T Lymphoblastic Leukemia
David Wu et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study
Martin Schrappe et al.
BLOOD (2011)
Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia
Patricia Stow et al.
BLOOD (2010)
Immaturity Associated Antigens Are Lost During Induction for T Cell Lymphoblastic Leukemia: Implications for Minimal Residual Disease Detection
Mikhail Roshal et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2010)
Normalization of Bone Marrow Aspirates for Hemodilution in Flow Cytometric Analyses
Michael R. Loken et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2009)
Quality Control of Flow Cytometry Data Analysis for Evaluation of Minimal Residual Disease in Bone Marrow From Acute Leukemia Patients During Treatment
Elisabet Björklund et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2009)
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study
Michael J. Borowitz et al.
BLOOD (2008)
Flow cytometric immunophenotyping for hematologic neoplasms
Fiona E. Craig et al.
BLOOD (2008)
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Bruno Paiva et al.
BLOOD (2008)
Standardization of Flow Cytometric Minimal Residual Disease Evaluation in Acute Lymphoblastic Leukemia: Multicentric Assessment Is Feasible
Michael Norbert Dworzak et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2008)
Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells
Giuseppe Gaipa et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2008)
Monitoring of minimal residual disease in acute myeloid leukemia
W Kern et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2005)
Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring
C Langebrake et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2005)
Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia
W Kern et al.
BLOOD (2004)
Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: Comparison with cytomorphologic, cytogenetic, and molecular genetic findings
D Voskova et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2004)
Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification
JF San Miguel et al.
BLOOD (2001)
High frequency of immunophenotype changes in acute myeloid leukemia at relapse:: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)
MR Baer et al.
BLOOD (2001)